Home / Deep Research / Familial Sick Sinus Syndrome

Familial Sick Sinus Syndrome

Familial Sick Sinus Syndrome (Familial Sinus Node Dysfunction): Disease Characteristics Research Report

2026-05-09
Falcon MONDO:0012061 Model: Edison Scientific Literature 30 citations

Familial Sick Sinus Syndrome (Familial Sinus Node Dysfunction): Disease Characteristics Research Report

Target Disease

  • Disease name: Familial Sick Sinus Syndrome (Familial SSS) / Familial Sinus Node Dysfunction (Familial SND)
  • Category: Genetic (familial inherited bradyarrhythmia / conduction disorder)

Executive overview

Familial sick sinus syndrome is an inherited predisposition to sinoatrial node dysfunction (SND)—a disorder of cardiac impulse formation and/or propagation from the sinoatrial node that can manifest as sinus bradycardia, sinus pauses/arrest, sinoatrial exit block, chronotropic incompetence, and tachycardia–bradycardia syndrome (often with atrial fibrillation). While SND/SSS is commonly age-related, heritable genetic variation contributes to earlier-onset or syndromic forms and to risk in the general population. Contemporary reviews emphasize that there is no established therapy that corrects underlying molecular causes, and management remains largely device-based (pacemakers). (maarel2023geneticsofsinoatrial pages 1-2, li2024cardiacconductiondiseases pages 3-4)

1. Disease Information

1.1 What is the disease?

  • SSS is described as a complex arrhythmia “characterized by pathological sinus bradycardia, sinoatrial block, or alternating atrial brady- and tachyarrhythmias” and is a leading indication for permanent pacing. (thorolfsdottir2021geneticinsightinto pages 2-3)
  • Recent mechanistic reviews summarize SND as abnormalities of SAN impulse formation/propagation manifesting as sinus bradycardia, sinus pauses, SAN exit block, and tachycardia–bradycardia syndrome. (li2024cardiacconductiondiseases pages 3-4)

Direct quote (definition): “SSS is … characterized by pathological sinus bradycardia, sinoatrial block, or alternating atrial brady- and tachyarrhythmias.” (thorolfsdottir2021geneticinsightinto pages 2-3)

1.2 Key identifiers (available from retrieved evidence)

Not available in retrieved evidence: MONDO ID, Orphanet ID, MeSH ID (would require direct database queries beyond the currently retrieved full texts).

1.3 Common synonyms / alternative names

  • Sick sinus syndrome (SSS)
  • Sinus node dysfunction (SND)
  • Sinoatrial node dysfunction
  • Familial sinus bradycardia (subset phenotype)

The 2023 review notes ICD-11 “sinus node dysfunction” as a broader term than SSS. (iskenderov2023familialformofa pages 1-3)

1.4 Evidence sources

The report is derived from: - Aggregated disease-level reviews (2023–2024) and guideline summaries (pediatric CIED pacing). (maarel2023geneticsofsinoatrial pages 1-2, li2024cardiacconductiondiseases pages 3-4, silvetti2024newguidelinesof pages 1-2) - Primary human genetics (large GWAS/meta-analysis; family exome sequencing; family phenotype/genotype studies). (thorolfsdottir2021geneticinsightinto pages 2-3, zaragoza2016exomesequencingidentifies pages 1-2, schweizer2014thesymptomcomplex pages 1-2) - Functional in vitro and in silico modeling of variants (HCN4). (verkerk2023functionalcharacterizationof pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause (familial disease): germline genetic variants affecting sinoatrial node pacemaking and atrial conduction biology.

Recent reviews categorize causal mechanisms into: - Membrane clock (“M-clock”) perturbations (If, ICaL/ICaT, IK, NCX, INa) - Intracellular Ca2+ clock perturbations (SR Ca2+ release/buffering) - Structural/trafficking/nuclear envelope mechanisms (e.g., ankyrin-B, lamin A/C)

These are summarized in 2024 conduction-system review: SAN automaticity arises from coupling of “M clock” and “Ca2+ clock.” (li2024cardiacconductiondiseases pages 3-4)

2.2 Risk factors

Genetic risk factors

Non-genetic / clinical risk factors

Causal inference from human genetics

Mendelian randomization in the 2021 EHJ study supported a causal role for atrial fibrillation (AF) and lower heart rate in SSS development, while arguing against causal associations for BMI, cholesterol, triglycerides and type 2 diabetes. (thorolfsdottir2021geneticinsightinto pages 2-3)

2.3 Protective factors

No specific protective genetic variants or lifestyle protective factors were identified in the retrieved evidence. The MR analysis arguing against causality for BMI/lipids/T2D should not be interpreted as protective. (thorolfsdottir2021geneticinsightinto pages 2-3)

2.4 Gene–environment interactions

The 2024 review describes strong autonomic modulation of SAN rate (sympathetic vs parasympathetic) and notes vagal tone can accentuate bradycardia in pacemaker-current impairment; in modeling, HCN4 A414G–related bradycardia becomes more prominent under vagal tone. (verkerk2023functionalcharacterizationof pages 1-2, li2024cardiacconductiondiseases pages 3-4)

3. Phenotypes

3.1 Core phenotype set (with suggested HPO terms)

Below are key familial SSS/SND manifestations supported by the retrieved literature.

  1. Sinus bradycardia (symptom/sign)
  2. Suggested HPO: HP:0001388 (Bradycardia)

  3. SAN dysfunction yields bradycardia with P-wave rate < ~60/min as an ECG correlate described in a 2023 genetics review. (maarel2023geneticsofsinoatrial pages 2-3)

  4. Sinus arrest / sinus pauses (sign; ECG/Holter abnormality)

  5. Suggested HPO: HP:0030637 (Sinus arrest) (term suggestion; exact HPO mapping should be verified)

  6. Included in SND manifestations in 2023–2024 reviews. (maarel2023geneticsofsinoatrial pages 1-2, li2024cardiacconductiondiseases pages 3-4)

  7. Sinoatrial exit block (ECG abnormality)

  8. Suggested HPO: HP:0011700 (Sinoatrial block) (term suggestion; verify in HPO)

  9. Absence of a P wave at expected intervals described as SAN exit block. (maarel2023geneticsofsinoatrial pages 2-3)

  10. Chronotropic incompetence (functional abnormality)

  11. Suggested HPO: HP:0031645 (Chronotropic incompetence) (term suggestion; verify)

  12. Explicitly described as an SND manifestation and used as pacing-indication criterion in pediatric guidelines (symptoms temporally associated with chronotropic incompetence). (maarel2023geneticsofsinoatrial pages 1-2, silvetti2024newguidelinesof pages 2-4)

  13. Tachycardia–bradycardia syndrome / AF susceptibility

  14. Suggested HPO: HP:0005110 (Atrial fibrillation); HP:0005111 (Atrial flutter)

  15. Familial SSS review reports tachy-brady syndrome in ≥50% of cases and describes AF as part of the syndrome spectrum. (iskenderov2023familialformof pages 1-3)

  16. Syncope / dizziness due to cerebral hypoperfusion

  17. Suggested HPO: HP:0001279 (Syncope); HP:0002321 (Vertigo) or dizziness term (verify)
  18. The 2023 review reports about 50% of patients have symptoms of cerebral hypoperfusion (dizziness, syncope). (iskenderov2023familialformof pages 1-3)

3.2 Temporal features (onset and progression)

3.3 Quality of life impact

Direct QoL instrument data (e.g., SF-36/EQ-5D) in familial SSS specifically were not retrieved in available full texts. However, symptoms (syncope, fatigue, exercise intolerance from chronotropic incompetence) and device dependence imply substantial impact; this is indirectly supported by pacing guideline emphasis on symptom correlation. (silvetti2024newguidelinesof pages 2-4, silvetti2024newguidelinesof pages 1-2)

4. Genetic / Molecular Information

4.1 Causal genes (high-confidence in retrieved evidence)

Recent expert reviews list familial SND genes across M-clock, Ca2+-clock, and structural/trafficking categories, including HCN4, SCN5A, KCNJ5, GNB2, CACNA1D, RYR2, CASQ2, ANK2, GJC1, MYH6. (li2024cardiacconductiondiseases pages 3-4)

A 2023 SAN genetics review additionally highlights Mendelian genes such as GNB5 (AR multisystem syndrome with bradycardia) and notes HCN4 and SCN5A as recurrent candidates. (maarel2023geneticsofsinoatrial pages 14-15)

4.2 Pathogenic variants and functional consequences (examples)

  • HCN4 A414G (heterozygous LoF): causes a large negative shift in activation (V1/2) and slowed gating, translating in a human SAN cell model to increased cycle length (bradycardia), especially under vagal tone. Quantitatively: V1/2 −19.9 mV, time constant shift −11.9 mV (both p<0.001). (verkerk2023functionalcharacterizationof pages 1-2)
  • HCN4 dominant-negative LoF: HCN4-G482R and other variants in familial SND + LV noncompaction; mutant subunits can be nonfunctional and exert dominant-negative effects on WT current (family study). (schweizer2014thesymptomcomplex pages 1-2)
  • SCN5A loss of function: Familial SSS linked to SCN5A; mechanisms include altered kinetics, impaired trafficking, or complete non-functionality across a panel of 13 familial-SSS-linked Nav1.5 mutants in a dedicated mechanistic study. (li2024cardiacconductiondiseases pages 3-4)
  • LMNA splice-site (c.357-2A>G): identified by exome sequencing in a family with SSS, dilated cardiomyopathy and sudden death; fibroblast data consistent with haploinsufficiency (monoallelic expression of normal allele). (zaragoza2016exomesequencingidentifies pages 1-2)

4.3 Modifier genes / oligogenicity

Oligogenic burden is suggested by: - LMNA family study reporting additional rare variants in genes including HCN4, TTN, etc. as potential modifiers. (zaragoza2016exomesequencingidentifies pages 1-2) - 2023 familial SSS review emphasizes “polygenic origin” and genetic heterogeneity. (iskenderov2023familialformofa pages 1-3)

4.4 Epigenetic information

No familial SSS-specific epigenetic profiling evidence was retrieved in the current evidence set.

4.5 Chromosomal abnormalities

No chromosomal abnormality evidence was retrieved.

5. Environmental Information

Familial SSS is primarily genetic, but secondary SSS can result from exogenous factors. The 2023 review lists medications and electrolyte disturbances (hyperkalemia/hypercalcemia) as causes of secondary SSS. (iskenderov2023familialformof pages 1-3)

No infectious triggers were identified in retrieved evidence.

6. Mechanism / Pathophysiology

6.1 Conceptual model (upstream → downstream causal chain)

  1. Genetic variant in pacemaker ion channel / Ca2+ handling / structural scaffolding / nuclear envelope gene
  2. Cellular electrophysiology defect in SAN pacemaker cells:
  3. If impairment (HCN4 LoF) → slower diastolic depolarization, longer cycle length; vagal tone can exacerbate effect (modeling). (verkerk2023functionalcharacterizationof pages 1-2)
  4. Membrane clock/Ca2+ clock uncoupling (review). (li2024cardiacconductiondiseases pages 3-4)
  5. Sodium current reduction (SCN5A LOF) → impaired impulse initiation/propagation (reviewed). (li2024cardiacconductiondiseases pages 3-4)
  6. Tissue/organ-level phenotype: SAN exit block, bradycardia, pauses; atrial remodeling and susceptibility to AF; potential overlap with cardiomyopathy (LMNA). (li2024cardiacconductiondiseases pages 3-4, zaragoza2016exomesequencingidentifies pages 1-2)

6.2 Molecular pathways and processes (with ontology suggestions)

  • GO Biological Process (suggestions):
  • regulation of heart rate
  • cardiac muscle cell action potential
  • sinoatrial node cell development/differentiation

  • regulation of membrane depolarization

  • Key mechanistic themes from 2024 review: coupling of M-clock (ICaL, ICaT, IK, If, NCX) with Ca2+ clock (SR Ca2+ release via RyR2). (li2024cardiacconductiondiseases pages 3-4)

6.3 Cell types (CL term suggestions)

  • Sinoatrial node pacemaker cardiomyocyte (CL term suggestion; exact CL ID requires ontology lookup)

6.4 Tissue and anatomy (UBERON suggestions)

  • Sinoatrial node (UBERON term suggestion)
  • Right atrium (UBERON term suggestion)

The 2023 SAN genetics review describes the SAN as a small structure of thousands of pacemaker cardiomyocytes at the junction of venous return and right atrium. (maarel2023geneticsofsinoatrial pages 2-3)

6.5 Advanced molecular profiling

No transcriptomic/proteomic/metabolomic disease signatures were directly retrieved for familial SSS in this evidence set.

7. Anatomical Structures Affected

  • Primary organ/system: Heart; cardiac conduction system (SAN; atrial conduction)
  • Secondary involvement: atria (AF risk); overlap cardiomyopathy/conduction disease in LMNA pedigrees (dilated cardiomyopathy, SCD). (zaragoza2016exomesequencingidentifies pages 1-2)

8. Temporal Development

9. Inheritance and Population

9.1 Inheritance patterns

Familial SSS includes both autosomal dominant and autosomal recessive inheritance patterns depending on gene/variant class (e.g., HCN4 commonly AD; SCN5A can be recessive in congenital forms). (iskenderov2023familialformofa pages 6-7)

9.2 Epidemiology and statistics

From the 2023 familial SSS review: - Overall annual incidence: ~1 per 1,000 in people ≥45 years. (iskenderov2023familialformof pages 1-3) - In heart disease patients >65: 1 in 600. (iskenderov2023familialformof pages 1-3) - Age- and race-standardized rates: 0.8 and 0.9 per 1,000 person-years in women and men. (iskenderov2023familialformof pages 1-3)

From the large human genetics study: - Study size: meta-analysis included 6,189 cases in one excerpt and ~6,469 in abstract (depending on excerpted sections), and large control populations, highlighting that SSS has both rare familial and polygenic components. (thorolfsdottir2021geneticinsightinto pages 2-3)

9.3 Penetrance/expressivity and modifiers

10. Diagnostics

10.1 Clinical tests

  • ECG / rhythm monitoring is central. The 2023 familial SSS review states diagnosis remains primarily electrocardiographic. (iskenderov2023familialformof pages 1-3)
  • The 2023 SAN genetics review describes ECG correlates: P-wave reflects SAN-initiated atrial activation; SAN dysfunction yields bradycardia, exit block (missing P wave at expected times), and ectopic atrial activation (altered P-wave morphology). (maarel2023geneticsofsinoatrial pages 2-3)
  • Holter / longer-term monitoring: used to quantify pauses and relate symptoms to rhythm; explicitly used as outcome in pacing trials in CHD with SND. (NCT03361189 chunk 2)

10.2 Genetic testing strategy (real-world approach)

Given genetic heterogeneity across ion channels, Ca2+ handling, and structural genes, recent clinical reviews suggest that single-gene testing is often insufficient and that multi-gene panels and/or exome sequencing may be needed—illustrated by: - Exome sequencing to identify LMNA splice-site mutation plus candidate modifiers in a large pedigree. (zaragoza2016exomesequencingidentifies pages 1-2) - Reviews cataloging multiple gene classes for familial SND. (li2024cardiacconductiondiseases pages 3-4)

10.3 Differential diagnosis

Not systematically enumerated in retrieved evidence; however, secondary causes (drugs/electrolytes) should be excluded when diagnosing familial primary SSS. (iskenderov2023familialformof pages 1-3)

11. Outcomes / Prognosis

Disease-specific survival statistics for familial SSS were not retrieved. However: - LMNA pedigrees demonstrate association with dilated cardiomyopathy and sudden cardiac death, indicating gene-specific higher-risk trajectories and need for structured surveillance. (zaragoza2016exomesequencingidentifies pages 1-2) - The 2023 familial SSS review associates SSS with increased risk of sudden cardiac death and emphasizes current management is symptom relief. (iskenderov2023familialformofa pages 1-3)

12. Treatment

12.1 Standard of care: cardiac pacing

Multiple sources agree that management is primarily device-based: - 2023 SAN genetics review notes no molecularly targeted therapy; management relies mainly on permanent electronic pacemaker implantation. (maarel2023geneticsofsinoatrial pages 1-2) - 2023 familial SSS review reports pacemaker implantation is indicated in ~30–50% of cases in Europe/USA. (iskenderov2023familialformof pages 1-3)

12.2 Pediatric pacing guideline evidence (2024)

Silvetti et al. (J Cardiovasc Dev Dis. Mar 2024, DOI: https://doi.org/10.3390/jcdd11040099) summarize pediatric consensus guidance: - For isolated SND, symptom correlation is central: - Class I: SND with symptoms correlated with age-inappropriate bradycardia (pacing indicated). (silvetti2024newguidelinesof pages 2-4) - Class IIa: symptoms temporally associated with chronotropic incompetence → rate-responsive pacemaker indicated. (silvetti2024newguidelinesof pages 2-4) - Device strategy highlights preferential atrial/dual chamber pacing and rate-responsive sensors to promote physiologic response. (silvetti2024newguidelinesof pages 4-5)

12.3 Emerging approaches / expert opinion

Recent expert opinion emphasizes research directions rather than established therapies: - Need for “genotype-targeted pharmacotherapy” and “biological pacemaker” development is emphasized in the 2023 familial SSS review. (iskenderov2023familialformof pages 9-10)

12.4 MAXO suggestions

  • Permanent pacemaker implantation (MAXO term suggestion; requires ontology lookup)
  • Implantable loop recorder insertion (MAXO term suggestion)

13. Prevention

14. Other Species / Natural Disease

No naturally occurring veterinary disease evidence was retrieved in the current evidence set.

15. Model Organisms and Experimental Models

Recent developments (prioritizing 2023–2024)

  1. Mechanism integration (M-clock/Ca-clock + heterogeneity): 2024 review emphasizes SAN automaticity arises from integrated “M clock” and “Ca2+ clock” mechanisms and heterogeneous subcellular signaling/cluster interactions (tonic entrainment). (li2024cardiacconductiondiseases pages 3-4)
  2. Functional quantification of HCN4 variant effects: 2023 functional study provides quantitative gating shifts explaining bradycardia and highlights vagal-tone interactions, providing a template for variant interpretation. (verkerk2023functionalcharacterizationof pages 1-2)
  3. Clinical guideline evolution in pediatrics: 2024 guideline summary prioritizes symptom correlation, introduces nuanced Class IIb situations, and points to increased use of physiologic pacing and loop recorders in inherited arrhythmia contexts. (silvetti2024newguidelinesof pages 2-4, silvetti2024newguidelinesof pages 1-2)

Applications and real-world implementation

Expert opinions and authoritative analyses

  • Expert Opinion on Therapeutic Targets (May 2024) highlights that current treatment for conduction disease manifested as bradycardia still relies primarily on cardiovascular implantable electronic devices, while arguing for translation of mechanistic knowledge to pharmacologic/genetic interventions. (li2024cardiacconductiondiseases pages 3-4)
  • Disease Models & Mechanisms (May 2023) review emphasizes genetic insights as a path to improved therapeutics but notes present reliance on pacemakers. (maarel2023geneticsofsinoatrial pages 1-2)

Relevant statistics and data (recent/large studies)

Clinical trials / registries (ClinicalTrials.gov)

The following registered studies explicitly relate to genetics/polymorphisms or management/monitoring relevant to SSS/SND: - NCT00314223 (2006; observational case-control): genetic polymorphisms in Taiwanese SSS patients; includes HCN1–4, SCN5A, KCNE and others; prospective. (NCT00314223 chunk 1) - URL: https://clinicaltrials.gov/study/NCT00314223 - NCT01310907 (2011; observational): gene polymorphisms in non-familial bradyarrhythmia (includes sinus node dysfunction and AV block). (NCT01310907 chunk 1) - URL: https://clinicaltrials.gov/study/NCT01310907 - NCT01310920 (2011; observational): angiotensinogen promoter polymorphisms in non-familial SSS. (NCT01310920 chunk 1) - URL: https://clinicaltrials.gov/study/NCT01310920 - NCT03361189 (UCLA; specialized pacing/CLS in CHD with significant SND): evaluates closed-loop stimulation vs standard rate response using stress testing and Holter outcomes; status TERMINATED in search metadata. (NCT03361189 chunk 2) - URL: https://clinicaltrials.gov/study/NCT03361189 - NCT00664807 (GAME Study; completed 2009): genetic/ECG markers for arrhythmia prediction in ICD populations; relevant as a genetic-marker study of arrhythmia risk; includes publication note with PMID 22247754. (NCT00664807 chunk 1) - URL: https://clinicaltrials.gov/study/NCT00664807

Gene-centric summary table

The following table consolidates genes, phenotypes, mechanisms, and evidence types from this evidence set.

Table (click to expand)
Gene Inheritance pattern / notes Key phenotype(s) Mechanistic theme Evidence type Key quantitative / statistical details Citation IDs
HCN4 Usually autosomal dominant in reported families; multiple heterozygous loss-of-function variants reported Sinus bradycardia, sinus node dysfunction, sinus arrest, chronotropic incompetence, atrial fibrillation; some families also show left ventricular noncompaction If / pacemaker current dysfunction in sinoatrial node cells Family studies, functional assay, review A414G heterozygous current showed −19.9 mV shift in V1/2 and −11.9 mV shift in (de)activation time constant (both p<0.001); mutant channels can act dominant-negatively; HCN4 is described as the predominant human SAN HCN isoform (schweizer2014thesymptomcomplex pages 1-2, verkerk2023functionalcharacterizationof pages 1-2, maarel2023geneticsofsinoatrial pages 1-2, li2024cardiacconductiondiseases pages 3-4, maarel2023geneticsofsinoatrial pages 14-15)
SCN5A Familial SSS can be autosomal recessive (classically congenital SSS1) or dominant in some families; compound heterozygous and homozygous cases reported Congenital/childhood or early-onset sick sinus syndrome, severe bradycardia, sinus pauses/arrest, atrial arrhythmias, overlap with Brugada syndrome / conduction disease INa / sodium channel loss of function; gating defects and trafficking defects Family studies, mechanistic functional studies, case reports, review 13 familial SSS-linked Nav1.5 mutants were grouped mechanistically into altered kinetics, impaired trafficking, or non-functional channels; recessive SCN5A cause recognized as SSS1 (OMIM 608567) (iskenderov2023familialformofa pages 6-7, zaragoza2016exomesequencingidentifies pages 1-2, sanner2021anovelscn5a pages 9-9, li2024cardiacconductiondiseases pages 3-4)
LMNA Reported as heterozygous splice-site–mediated familial disease; variable expressivity with cardiomyopathy/conduction overlap Adult-onset sick sinus syndrome, conduction disease, dilated cardiomyopathy, sudden cardiac death, atrial disease/standstill overlap Nuclear lamina dysfunction / haploinsufficiency Exome-sequenced family study, review, rare-variant association LMNA c.357-2A>G showed monoallelic normal-allele expression consistent with haploinsufficiency; rare-variant analyses in large bradyarrhythmia datasets implicated LMNA for all bradyarrhythmia subtypes (zaragoza2016exomesequencingidentifies pages 1-2, iskenderov2023familialformofa pages 6-7)
ANK2 Loss-of-function associated with incomplete penetrance and likely modifier effects Sinus bradycardia, atrial fibrillation, broader complex arrhythmia phenotypes Trafficking / membrane scaffolding (ankyrin-B-dependent ion channel localization) Review, cited family/genetic evidence No disease-specific effect size given in retrieved context; highlighted as a familial SSS contributor with environmental/genetic modifiers likely influencing expression (iskenderov2023familialformofa pages 6-7, li2024cardiacconductiondiseases pages 3-4)
MYH6 Rare coding variation implicated in SSS susceptibility; likely variable expressivity Sick sinus syndrome; atrial electrical/mechanical dysfunction overlap Contractile / structural cardiomyocyte program affecting atrial/SAN biology GWAS, review 2021 SSS GWAS highlighted a previously reported MYH6 missense signal among associated loci (thorolfsdottir2021geneticinsightinto pages 2-3, li2024cardiacconductiondiseases pages 3-4)
RYR2 Familial contributor noted in reviews; may overlap with other inherited arrhythmia phenotypes Sinus bradycardia / SAN dysfunction, atrial arrhythmias Ca2+ clock / SR Ca2+ release Review, cited experimental studies No direct human effect estimate in retrieved context; repeatedly cited as part of calcium-handling gene set linked to familial SND/SSS (iskenderov2023familialformofa pages 1-3, li2024cardiacconductiondiseases pages 3-4, iskenderov2023familialformofa pages 9-10)
CASQ2 Familial contributor; often discussed through calcium-handling models and arrhythmia overlap Sinoatrial node dysfunction, bradycardia, atrial arrhythmias Ca2+ clock / SR Ca2+ buffering Review, animal-model-backed mechanistic evidence Retrieved context notes CASQ2 deletion can cause SAN dysfunction in models; no human quantitative estimate given in context (iskenderov2023familialformofa pages 1-3, li2024cardiacconductiondiseases pages 3-4, iskenderov2023familialformofa pages 9-10)
CACNA1D Mendelian contributor in some families; channelopathy affecting pacemaker depolarization Sinus bradycardia / SAN dysfunction Ca2+ clock / L-type Ca2+ current supporting diastolic depolarization Review No quantitative penetrance estimate in retrieved context; listed among core familial SND genes in 2024 review (iskenderov2023familialformofa pages 6-7, li2024cardiacconductiondiseases pages 3-4)
GNB2 / GNB5 GNB2 linked to familial sinus-node/AV conduction dysfunction; GNB5 often autosomal recessive multisystem syndrome with bradycardia Sinus bradycardia, SAN dysfunction, AV conduction disease; GNB5 additionally cognitive/neurodevelopmental features G-protein signaling / autonomic-pacemaker coupling Review No effect size given in retrieved context; both genes highlighted as Mendelian contributors to SAN disease (li2024cardiacconductiondiseases pages 3-4, maarel2023geneticsofsinoatrial pages 14-15)
KRT8 Common/low-frequency risk variant rather than classic Mendelian familial gene in available evidence SSS susceptibility; apparently more SSS-specific than broader arrhythmia spectrum in the cited GWAS Intermediate filament / structural cell integrity GWAS/meta-analysis p.Gly62Cys had OR 1.44 in heterozygotes and OR 13.99 in homozygotes; described as the only reported SSS variant in that study not associating with other arrhythmias/CVD (thorolfsdottir2021geneticinsightinto pages 2-3)
TTN May act as susceptibility / modifier gene; also appears in families with compound variation Sick sinus syndrome, pacemaker implantation risk, atrial fibrillation overlap, cardiomyopathy overlap Sarcomeric / structural myocardial substrate Family study, GWAS/rare-variant analyses, review 2025 bradyarrhythmia genetics summary in prior search implicated TTN for pacemaker implantation; 2018 family report found TTN variant alongside CACNA1C variants in SSS pedigree (li2024cardiacconductiondiseases pages 3-4)
CACNA1C Candidate familial susceptibility gene in compound-variant families Sinus bradycardia / SSS, early repolarization, atrial fibrillation in reported pedigree Ca2+ channel / membrane clock Family study, review 2018 family carried CACNA1C p.V596M and p.A1782T with TTN p.R16472H; complex overlapping variants associated with more severe phenotype in proband (li2024cardiacconductiondiseases pages 3-4)

Table: This table summarizes the main genes implicated in familial sick sinus syndrome/sinus node dysfunction, with inheritance patterns, phenotypes, mechanisms, and evidence types supported by the retrieved workspace context. It is useful as a compact gene-to-phenotype/mechanism map for the disease knowledge base.

Key limitations of the current evidence pull

  • PMIDs were not consistently available in the retrieved full-text excerpts for multiple 2023–2024 papers (e.g., DMM 2023 review; Expert Opin Ther Targets 2024 review; MDPI guideline summary), despite DOIs and URLs being available. (maarel2023geneticsofsinoatrial pages 1-2, li2024cardiacconductiondiseases pages 3-4, silvetti2024newguidelinesof pages 1-2)
  • MONDO, Orphanet, and MeSH identifiers were not present in the retrieved texts; direct database lookup would be needed for a complete identifier panel.
  • Quantitative phenotype frequencies are limited in the retrieved evidence (beyond the 2023 review’s symptom/tachy-brady estimates and GWAS effect sizes).

References

  1. (maarel2023geneticsofsinoatrial pages 1-2): Lieve E. van der Maarel, Alex V. Postma, and Vincent M. Christoffels. Genetics of sinoatrial node function and heart rate disorders. Disease Models & Mechanisms, May 2023. URL: https://doi.org/10.1242/dmm.050101, doi:10.1242/dmm.050101. This article has 21 citations and is from a domain leading peer-reviewed journal.

  2. (li2024cardiacconductiondiseases pages 3-4): Tingting Li, Qussay Marashly, Jitae A. Kim, Na Li, and Mihail G. Chelu. Cardiac conduction diseases: understanding the molecular mechanisms to uncover targets for future treatments. Expert Opinion on Therapeutic Targets, 28:385-400, May 2024. URL: https://doi.org/10.1080/14728222.2024.2351501, doi:10.1080/14728222.2024.2351501. This article has 5 citations and is from a peer-reviewed journal.

  3. (thorolfsdottir2021geneticinsightinto pages 2-3): Rosa B Thorolfsdottir, Gardar Sveinbjornsson, Hildur M Aegisdottir, Stefania Benonisdottir, Lilja Stefansdottir, Erna V Ivarsdottir, Gisli H Halldorsson, Jon K Sigurdsson, Christian Torp-Pedersen, Peter E Weeke, Søren Brunak, David Westergaard, Ole B Pedersen, Erik Sorensen, Kaspar R Nielsen, Kristoffer S Burgdorf, Karina Banasik, Ben Brumpton, Wei Zhou, Asmundur Oddsson, Vinicius Tragante, Kristjan E Hjorleifsson, Olafur B Davidsson, Sridharan Rajamani, Stefan Jonsson, Bjarni Torfason, Atli S Valgardsson, Gudmundur Thorgeirsson, Michael L Frigge, Gudmar Thorleifsson, Gudmundur L Norddahl, Anna Helgadottir, Solveig Gretarsdottir, Patrick Sulem, Ingileif Jonsdottir, Cristen J Willer, Kristian Hveem, Henning Bundgaard, Henrik Ullum, David O Arnar, Unnur Thorsteinsdottir, Daniel F Gudbjartsson, Hilma Holm, Kari Stefansson, Steffen Andersen, Christian Erikstrup, Thomas F Hansen, Henrik Hjalgrim, Gregor Jemec, Poul Jennum, Mette Nyegaard, Mie T Bruun, Mikkel Petersen, Thomas Werge, and Per I Johansson. Genetic insight into sick sinus syndrome. European Heart Journal, 42:1959-1971, Feb 2021. URL: https://doi.org/10.1093/eurheartj/ehaa1108, doi:10.1093/eurheartj/ehaa1108. This article has 66 citations and is from a highest quality peer-reviewed journal.

  4. (iskenderov2023familialformof pages 1-3): BH Iskenderov. Familial form of sick sinus syndrome. new views on polygenic origin and prospects for gene therapy. Unknown journal, 2023.

  5. (iskenderov2023familialformofa pages 1-3): BH Iskenderov. Familial form of sick sinus syndrome. new views on polygenic origin and prospects for gene therapy. Unknown journal, 2023.

  6. (silvetti2024newguidelinesof pages 1-2): Massimo Stefano Silvetti, Diego Colonna, Fulvio Gabbarini, Giulio Porcedda, Alessandro Rimini, Antonio D’Onofrio, and Loira Leoni. New guidelines of pediatric cardiac implantable electronic devices: what is changing in clinical practice? Journal of Cardiovascular Development and Disease, 11:99, Mar 2024. URL: https://doi.org/10.3390/jcdd11040099, doi:10.3390/jcdd11040099. This article has 16 citations.

  7. (zaragoza2016exomesequencingidentifies pages 1-2): Michael V. Zaragoza, Lianna Fung, Ember Jensen, Frances Oh, Katherine Cung, Linda A. McCarthy, Christine K. Tran, Van Hoang, Simin A. Hakim, and Anna Grosberg. Exome sequencing identifies a novel lmna splice-site mutation and multigenic heterozygosity of potential modifiers in a family with sick sinus syndrome, dilated cardiomyopathy, and sudden cardiac death. PLOS ONE, 11:e0155421, May 2016. URL: https://doi.org/10.1371/journal.pone.0155421, doi:10.1371/journal.pone.0155421. This article has 43 citations and is from a peer-reviewed journal.

  8. (schweizer2014thesymptomcomplex pages 1-2): Patrick A. Schweizer, Julian Schröter, Sebastian Greiner, Jan Haas, Pessah Yampolsky, Derliz Mereles, Sebastian J. Buss, Claudia Seyler, Claus Bruehl, Andreas Draguhn, Michael Koenen, Benjamin Meder, Hugo A. Katus, and Dierk Thomas. The symptom complex of familial sinus node dysfunction and myocardial noncompaction is associated with mutations in the hcn4 channel. Journal of the American College of Cardiology, 64 8:757-67, Aug 2014. URL: https://doi.org/10.1016/j.jacc.2014.06.1155, doi:10.1016/j.jacc.2014.06.1155. This article has 172 citations and is from a highest quality peer-reviewed journal.

  9. (verkerk2023functionalcharacterizationof pages 1-2): Arie Verkerk and Ronald Wilders. Functional characterization of the a414g loss-of-function mutation in hcn4 associated with sinus bradycardia. Cardiogenetics, 13:117-134, Aug 2023. URL: https://doi.org/10.3390/cardiogenetics13030012, doi:10.3390/cardiogenetics13030012. This article has 1 citations.

  10. (maarel2023geneticsofsinoatrial pages 2-3): Lieve E. van der Maarel, Alex V. Postma, and Vincent M. Christoffels. Genetics of sinoatrial node function and heart rate disorders. Disease Models & Mechanisms, May 2023. URL: https://doi.org/10.1242/dmm.050101, doi:10.1242/dmm.050101. This article has 21 citations and is from a domain leading peer-reviewed journal.

  11. (silvetti2024newguidelinesof pages 2-4): Massimo Stefano Silvetti, Diego Colonna, Fulvio Gabbarini, Giulio Porcedda, Alessandro Rimini, Antonio D’Onofrio, and Loira Leoni. New guidelines of pediatric cardiac implantable electronic devices: what is changing in clinical practice? Journal of Cardiovascular Development and Disease, 11:99, Mar 2024. URL: https://doi.org/10.3390/jcdd11040099, doi:10.3390/jcdd11040099. This article has 16 citations.

  12. (maarel2023geneticsofsinoatrial pages 14-15): Lieve E. van der Maarel, Alex V. Postma, and Vincent M. Christoffels. Genetics of sinoatrial node function and heart rate disorders. Disease Models & Mechanisms, May 2023. URL: https://doi.org/10.1242/dmm.050101, doi:10.1242/dmm.050101. This article has 21 citations and is from a domain leading peer-reviewed journal.

  13. (iskenderov2023familialformofa pages 6-7): BH Iskenderov. Familial form of sick sinus syndrome. new views on polygenic origin and prospects for gene therapy. Unknown journal, 2023.

  14. (NCT03361189 chunk 2): Jeremy P. Moore, MD. Specialized Pacing for Patients With Congenital Heart Disease. University of California, Los Angeles. 2021. ClinicalTrials.gov Identifier: NCT03361189

  15. (silvetti2024newguidelinesof pages 4-5): Massimo Stefano Silvetti, Diego Colonna, Fulvio Gabbarini, Giulio Porcedda, Alessandro Rimini, Antonio D’Onofrio, and Loira Leoni. New guidelines of pediatric cardiac implantable electronic devices: what is changing in clinical practice? Journal of Cardiovascular Development and Disease, 11:99, Mar 2024. URL: https://doi.org/10.3390/jcdd11040099, doi:10.3390/jcdd11040099. This article has 16 citations.

  16. (iskenderov2023familialformof pages 9-10): BH Iskenderov. Familial form of sick sinus syndrome. new views on polygenic origin and prospects for gene therapy. Unknown journal, 2023.

  17. (NCT00314223 chunk 1): Identification of Gene Polymorphism in Patients With Sick Sinus Syndrome in Chinese Population in Taiwan. China Medical University Hospital. 2006. ClinicalTrials.gov Identifier: NCT00314223

  18. (NCT01310907 chunk 1): Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia. China Medical University Hospital. 2011. ClinicalTrials.gov Identifier: NCT01310907

  19. (NCT01310920 chunk 1): The Role of Angiotensinogen Gene Polymorphism in the Pathogenesis of Non-familial Sick Sinus Syndrome. China Medical University Hospital. 2011. ClinicalTrials.gov Identifier: NCT01310920

  20. (NCT00664807 chunk 1): Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study). Medtronic Corporate Technologies and New Ventures. 2008. ClinicalTrials.gov Identifier: NCT00664807

  21. (sanner2021anovelscn5a pages 9-9): Karolina Sanner, Johanna Mueller-Leisse, Christos Zormpas, David Duncker, Andreas Leffler, and Christian Veltmann. A novel scn5a variant causes temperature-sensitive loss of function in a family with symptomatic brugada syndrome, cardiac conduction disease, and sick sinus syndrome. Cardiology, 146:754-762, Jul 2021. URL: https://doi.org/10.1159/000518210, doi:10.1159/000518210. This article has 7 citations and is from a peer-reviewed journal.

  22. (iskenderov2023familialformofa pages 9-10): BH Iskenderov. Familial form of sick sinus syndrome. new views on polygenic origin and prospects for gene therapy. Unknown journal, 2023.